Collaborative Awards to Support Microphysiological System Pilot Studies in Type 2 Diabetes Research
ID: 360659Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/360659
Timeline
    Description

    The National Institutes of Health (NIH) is offering a grant opportunity titled "Collaborative Awards to Support Microphysiological System Pilot Studies in Type 2 Diabetes Research." This initiative aims to solicit applications for research focused on microphysiological systems (MPSs) that model type 2 diabetes, encouraging collaborative investigations that combine expertise in bioengineering, diabetes biology, and human metabolism. The program is particularly significant as it seeks to advance understanding of metabolic tissue interactions and the heterogeneity of type 2 diabetes, supporting small pilot studies to generate preliminary data. The estimated total funding for this program is $1,000,000, with four awards expected, and interested applicants can reach out to Dr. Albert J. Hwa at albert.hwa@nih.gov or by phone at 301-451-1525 for further information. The application process is anticipated to open with a synopsis posted on April 1, 2026, and close on July 5, 2026, with awards expected to be made in January 2027.

    Point(s) of Contact
    Albert J. Hwa, PhD
    (301) 451-1525
    albert.hwa@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for collaborative research projects focused on type 1 diabetes, specifically utilizing biosamples and data from established clinical studies. The objective is to advance the understanding of the disease's etiology and pathogenesis, with funding available for studies that aim to explore disease mechanisms, delay onset, and improve prevention strategies. A total of $5.5 million is committed for up to four awards in Fiscal Years 2026 and 2027, with application deadlines beginning on May 26, 2025, and a final submission date of March 9, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for Diabetes Research Centers (P30 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for Diabetes Research Centers (P30 Clinical Trial Optional), aimed at enhancing research collaboration and innovation in diabetes and related metabolic disorders. This initiative seeks to establish a community of preclinical and clinical researchers, providing access to specialized resources and a Pilot and Feasibility Program to foster significant advancements beyond individual project capabilities. With an estimated total program funding of $18.2 million and an award ceiling of $1 million, the NIH anticipates making approximately seven awards, encouraging applications from a diverse range of eligible entities, including non-domestic institutions and community-based organizations. Interested parties should prepare for the application process, as the estimated synopsis post date is July 30, 2025, with applications expected to be solicited by March 11, 2026, and awards anticipated by December 30, 2026. For further inquiries, contact Dr. Christopher J. Lynch at lynchcj@nih.gov or call 301-325-4232.
    New Generation of Glucose Control Technologies Incorporating AI/ML Tools/Strategies
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity titled "New Generation of Glucose Control Technologies Incorporating AI/ML Tools/Strategies," aimed at advancing research in diabetes control systems. This initiative seeks to overcome barriers to effective open- and closed-loop diabetes management through innovative approaches, including the development of AI/machine learning-driven tools, novel hormone delivery methods, and digital twin modeling to enhance decision support systems. With an estimated total program funding of $3 million, the NIH anticipates awarding approximately six grants, with applications expected to open in September 2025 and close by October 2025. Interested applicants can reach out to Guillermo Arreaza-Rubín at ga96b@nih.gov or call 301-594-4724 for further information.
    Advancing Research on the Application of Digital Health Technology to the Management of Type 2 Diabetes (R01- Clinical Trail Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Advancing Research on the Application of Digital Health Technology to the Management of Type 2 Diabetes (R01- Clinical Trial Required)." This initiative aims to explore the efficacy and clinical effectiveness of multimodality digital health technology approaches, such as continuous glucose monitoring and telemedicine, in the remote management of diabetes. The research is crucial for enhancing the understanding of diabetes management, prevention, diagnosis, and treatment, with a focus on improving health outcomes. The NIH anticipates awarding three grants for projects lasting up to five years, with application deadlines set for November 7, 2025, and October 6, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the detailed announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-26-315.html.
    Single Source for Establishing Pilot/Opportunity program for AI Models to Accelerate Diabetes Research (U24- Clinical Trials not allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a cooperative agreement opportunity titled "Single Source for Establishing Pilot/Opportunity program for AI Models to Accelerate Diabetes Research." This initiative aims to establish a pilot funding program at the University of California, San Diego, focusing on the development and validation of AI models to address the complexities of diabetes research, particularly its heterogeneity. The program seeks to integrate data science expertise into diabetes research, fostering multidisciplinary teams to create user-friendly AI models and use cases that demonstrate their potential in accelerating research efforts. Interested applicants can reach out to Dr. Xujing Wang at xujing.wang@nih.gov or by phone at 301-451-2862 for further information. The estimated project start date is February 1, 2027, with applications peer-reviewed and only meritorious submissions considered for funding.
    The Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal: Roadmap for Future Development (Cooperative Agreement, Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a cooperative agreement opportunity titled "The Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal: Roadmap for Future Development," aimed at enhancing the understanding of complex metabolic diseases, particularly Type 2 Diabetes (T2D). This initiative seeks to renew the AMP CMD UM1 program for an additional five years, focusing on the aggregation and collation of genetic data related to T2D and its complications, thereby facilitating research and therapeutic advancements in the field. The program is critical for leveraging human genetics to uncover disease mechanisms and potential biomarkers, with an estimated total funding of $3 million and the expectation of one award. Interested applicants, including small businesses and various organizations, should contact Dr. Norann Zaghloul at Norann.zaghloul@nih.gov or call 301-435-6677 for further details, with proposals due by March 1, 2026, and awards anticipated by December 1, 2026.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)," aimed at encouraging exploratory research to develop advanced microphysiological systems (MPS) that accurately replicate complex human nervous system architectures. This initiative seeks to facilitate studies on nervous system development, function, and aging, particularly in relation to neurological diseases. The R21 grant allows for a budget of up to $275,000 over two years, with applications opening on January 16, 2025, and a submission deadline of January 7, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium through a cooperative agreement. This initiative aims to advance research on cardiovascular disease in individuals with type 1 diabetes by soliciting applications for discovery and mechanistic studies, leveraging the resources of the existing CARE-T1D consortium formed in 2024. The program is particularly focused on hypothesis-driven research utilizing multi-omics and molecular approaches, encouraging collaboration among experts in related fields such as type 2 diabetes and atherosclerosis. The estimated total funding for this program is $4.5 million, with approximately eight awards expected to be made. Interested applicants can reach out to Dr. Chandima Nishadi De Abrew Rajapakse at Chandima.rajapakse@nih.gov or by phone at 240-429-5197. The application process is set to open with a synopsis posting on April 1, 2026, and will close on July 1, 2026, with awards anticipated by March 1, 2027.
    High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Impact, Interdisciplinary Science in NIDDK Research Areas" (PAR-25-277) aimed at supporting innovative research that addresses critical knowledge gaps in diabetes, digestive, and kidney diseases. This grant program encourages interdisciplinary approaches to foster discovery-based science and develop transformative technologies that can significantly impact the broader scientific community. Eligible applicants include a wide range of organizations, such as higher education institutions and nonprofits, with proposals accepted for projects lasting up to five years. Interested parties should ensure compliance with application guidelines and submit their proposals by the deadline of October 15, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-277.html.
    Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies," aimed at advancing research in stem cell-derived islet cell products for enhanced cell replacement therapy outcomes. This initiative seeks to stimulate studies focused on engineering the inherent characteristics of these products, which are derived from well-defined cell bank sources, to improve graft viability and function, particularly in the context of type 1 diabetes. The estimated total program funding is $3 million, with approximately six awards expected, and interested applicants are encouraged to prepare collaborative proposals ahead of the anticipated Notice of Funding Opportunity (NOFO) release on August 1, 2025. For further inquiries, potential applicants can contact Dr. Albert J. Hwa at albert.hwa@nih.gov or by phone at 301-451-1525.